Bridgebio Pharma Inc (BBIO) returns
Bridgebio Pharma returns over 5 years
$1,000 invested in Bridgebio Pharma five years ago was worth $1,518 at the close on October 30, 2026, with dividends reinvested: an average return of 8.7% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | +13.9% | — | $1,139 | -0.9% |
| 3 months | -8.8% | — | $912.47 | +2.1% |
| Year to date | -2.0% | — | $979.87 | +11.7% |
| 1 year | +18.3% | — | $1,183 | +12.4% |
| 3 years | +193.8% | +43.2% | $2,938 | +88.5% |
| 5 years | +51.8% | +8.7% | $1,518 | +76.0% |
Bridgebio Pharma return by calendar year
| Year | BBIO | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -2.0% | +11.7% | -13.7% |
| 2025 | +178.8% | +17.7% | +161.0% |
| 2024 | -32.0% | +24.9% | -56.9% |
| 2023 | +429.8% | +26.2% | +403.6% |
| 2022 | -54.3% | -18.2% | -36.1% |
| 2021 | -76.5% | +28.7% | -105.3% |
| 2020 | +102.9% | +18.4% | +84.5% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: BBIO financials
No forecast, no recommendation. This page describes Bridgebio Pharma Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.